In 2020, berotralstat (BCX7353), an oral, once-daily inhibitor of plasma kallikrein was approved in the United States and Japan for prophylaxis to prevent attacks of HAE in adults and pediatric patients 12 years and older [89]. The gene discussed is KLK4; the disease is hereditary angioedema.